Internal Medicine, Medical Oncology · Lubbock, TX
NPI
1679536387
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
4101 22nd Place
Lubbock, TX, 79410
Phone (806) 725-8000
Groups this clinician bills Medicare through
Medicare paid, 2024
$69K
975 services
Medicare patients, 2024
302
Average age 74
Drug cost, 2024
$2.4M
933 prescriptions
Company payments, 2025
$636
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Isaac Tafur was code 99214 (office e&m - established), 636 times for 190 patients. In total Isaac Tafur billed 975 services in 16 codes, and Medicare paid $69K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-02-26.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 636 | 190 | $66.80 | $42K |
| 99232 Hospital E&M - Subsequent | Facility | 112 | 63 | $58.95 | $6,602 |
| 99213 Office E&M - Established | Facility | 85 | 70 | $42.04 | $3,574 |
| 99205 Office E&M - New | Facility | 46 | 46 | $132.72 | $6,105 |
| 99215 Office E&M - Established | Facility | 34 | 29 | $103.64 | $3,524 |
| 99223 Hospital E&M - Initial | Facility | 31 | 31 | $131.30 | $4,070 |
| 99233 Hospital E&M - Subsequent | Facility | 20 | 14 | $90.06 | $1,801 |
By year: 2022 $53K for 783 services; 2023 $52K for 751 services; 2024 $69K for 975 services.
Medicare prescription drug claims, 2024
In 2024, the drug Isaac Tafur prescribed most often to Medicare patients was Anastrozole, with 208 prescriptions and refills. In total Isaac Tafur wrote 933 Medicare prescriptions that cost $2.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 208 | 535 | 63 | $2,799 |
| Potassium Chloride Generic | 62 | 112 | 20 | $1,941 |
| Ondansetron Hcl Generic | 53 | 53 | 26 | $520 |
| Ondansetron Odt Ondansetron | 51 | 51 | 38 | $780 |
| Abiraterone Acetate Generic | 47 | 47 | Under 11 | $175K |
| Promethazine Hcl Generic | 44 | 44 | 21 | $302 |
| Prednisone Generic | 34 | 50 | Under 11 | $229 |
| Diphenoxylate-Atropine Diphenoxylate Hcl/Atropine | 30 | 30 | 14 | $377 |
| Eliquis Apixaban | 26 | 38 | Under 11 | $21K |
| Pomalyst Pomalidomide | 26 | 26 | Under 11 | $337K |
| Letrozole Generic | 23 | 67 | Under 11 | $1,162 |
| Ibrance Palbociclib | 21 | 21 | Under 11 | $335K |
| Gabapentin Generic | 20 | 34 | Under 11 | $479 |
| Lactulose Generic | 18 | 18 | Under 11 | $257 |
| Tamoxifen Citrate Generic | 16 | 41 | Under 11 | $487 |
Brand drugs: 162 claims; generic drugs: 771 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Isaac Tafur $636 ($636 in general payments such as food, travel and fees) from 14 companies. The largest payer was Janssen Biotech, Inc. with $121.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 5 | $121 |
| Pfizer Inc. PFE | 5 | $101 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $85.6 |
| Incyte Corporation INCY | 2 | $41.73 |
| Jazz Pharmaceuticals Inc. JAZZ | 1 | $36.29 |
| Abbvie Inc. ABBV | 2 | $36.11 |
| Novartis Pharmaceuticals Corporation NVS | 1 | $33.76 |
| Merck Sharp & Dohme LLC MRK | 1 | $32.51 |
| Array Biopharma Inc PFE | 1 | $26.28 |
| Celgene Corporation BMY | 1 | $26.23 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.